Currently, the optimal biomarkers used to detect AD processes early in the course of the disease are pathological marker Aβ and tau by Positron Emission Tomography (PET) imaging or cerebrospinal fluid detection (CSF) (Lista et al., 2014; Jack et al., 2018). Here, MAPT is linked to Alzheimer disease.